<DOC>
	<DOCNO>NCT01259336</DOCNO>
	<brief_summary>The purpose study determine whether itraconazole effective treatment chronic cavitary pulmonary aspergillosis</brief_summary>
	<brief_title>Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis</brief_title>
	<detailed_description>The role itraconazole still clear treatment chronic cavitary pulmonary aspergillosis ( CCPA ) . Some study show beneficial role itraconazole reduce hemoptysis . So present study aim analyze role itraconazole CCPA .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>1 . 1 . Clinical symptom : presence chronic pulmonary/systemic symptom last â‰¥ six week . 2 . Radiological finding : Evidence slowly progressive pulmonary lesion weeksmonths include cavity surround inflammation . presence intracavitary mass surround crescent air , presence pleural thicken peripheral lesion . 3 . Microbiological/Immunological finding : Positive result aspergillus precipitin test , demonstration aspergillus hypha sputum BAL fluid culture BAL/sputum grow aspergillus specie . 2 . The diagnosis CCPA make 1 . Patient satisfies least 1 , 2a 2b and/ 3rd criterion . 2 . FNAC cavity wall consider atypical case 3 . 1 . Invasive aspergillosis 2 . Allergic bronchopulmonary aspergillosis ( ABPA ) 3 . Active tuberculosis malignancy 4 . Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>chronic cavitary pulmonary aspergillosis</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>fungal ball</keyword>
	<keyword>mycetoma</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>